

MARYLAND PHARMACY PROGRAM

Medicaid - Pharmacy Assistance — Pharmacy Discount

No. 4B Friday, December 12, 2003

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene's (DHMH) *Maryland Pharmacy Program* (MPP) has developed the **Maryland Pharmacy Program Advisory**. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MPP representative at 410-767-5395.

REVISED PREFERRED DRUG LIST (PDL): CUMULATIVE UPDATE FOR RETAIL PHARMACIES As of December 12, 2003

The Department of Health and Mental Hygiene's Pharmacy and Therapeutics Committee continues development of the Preferred Drug List (PDL). This Advisory provides pharmacies sufficient notice of the additional therapeutic classes. **This Advisory #4B and the attached PDL supersede** any former PDL versions. Please note that all Maryland Medicaid rules and edits remain in effect. Full consideration for the recipient continues to be a top priority. The prescriber and pharmacist are encouraged to review the available options for drug therapy within the Preferred Drug List. Recipients having problems obtaining prescribed medications from the pharmacy may call the Maryland Pharmacy Access Hotline at 1-800-492-5231. If you (the pharmacy) have any questions, contact the Department at 410-767-1455.

For Additional Information

To obtain current and additional information about the Maryland Preferred Drug List, please feel free to visit the following websites:

Department of Health and Mental Hygiene http://www.dhmh.state.md.us/mma/mpap/prefdruglist.html

Provider Synergies http://providersynergies.com

First Health Services Corporation http://mdmedicaidrx.fhsc.com

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

Only drugs listed within the therapeutic categories are affected by the PDL. Therapeutic categories not listed here are not part of the PDL and will continue to be covered for Maryland Pharmacy Program patients.

ANALGESIC

Anti-Migraine Agents, Triptans (Anti-Migraine Preparations) Effective as of January 7, 2004

Preferred

Amerge Imitrex (oral, nasal & subg)

Maxalt, MLT

Requires Prior Authorization

Axert Frova Relpax

Zomig, Nasal, ZMT

Nonsteroidal Anti-Inflammatories/COX II Inhibitor (NSAIDS, Cyclooxygenase Inhibitor – Type)

Effective as of November 19, 2003

Preferred

diclofenac potassium (Cataflam) diclofenac sodium, XL (Voltaren, XR)

etodolac, XL (Lodine, XL) fenoprofen (Nalfon) flurbiprofen (Ansaid) ibuprofen (Motrin)

indomethacin, SR (Indocin, SR) ketoprofen (Orudis, Oruvail)

ketorolac (Toradol)

meclofenamate (Meclomen)

nabumetone (Relafen) naproxen (Naprosyn)

naproxen sodium. DS (Anaprox. DS)

oxaprozin (Daypro) piroxicam (Feldene) sulindac (Clinoril)

tolmetin, DS (Tolectin, DS)

Requires Prior Authorization

Arthrotec Bextra Celebrex Mobic Ponstel Vioxx

Narcotic Analgesics

Effective as of January 7, 2004

Preferred

acetaminophen w/codeine (Oral) aspirin w/codeine (Oral)

Avinza (Oral)

butalbital/apap/caffeine (Oral)

butalbital/caff/apap/codeine (Oral) codeine phosphate/sulfate (oral)

Duragesic (Transderm)

hydrocodone bit-ibuprofen (Oral)

hydrocodone w/acetaminophen

(Oral)

hydromorphone HCI (Oral)

Kadian (Oral)

meperidine HCI (Oral)

morphine sulfate/IR (Oral

oxycodone HCI (Oral)

oxycodone w/acetaminophen(Oral)

oxycodone w/aspirin (Oral)

Panlor DC/SS (Oral)

pentazocine-naloxone (Oral)

propoxyphene HCI/compound

(Oral)

propoxyphene HCI w/apap (Oral)

propoxyphene napsylate w/apap

(Oral)

roxicodone (Oral)

tramadol HCI (oral)

Ultracet (Oral)

Requires Prior Authorization

Darvon-N (oral)
Percocet (Oral)
Oxycontin (Oral)
Synalgos -DC (Oral)
Actig (Buccal)

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

ANTI-INFECTIVES

Antifungals, Oral (Antifungal Agents, Antifungal Antibiotics) Effective as of January 21, 2004

Preferred

griseofulvin (Fulvicin) ketoconazole (Nizoral) nystatin

Diflucan Grifulvin V Lamisil

Requires Prior Authorization

Ancobon Mycelex Troche Mycostatin Pastilles Sporanox Vfend

Antifungals, Topical (Topical Antifungals) Effective as of January 21, 2004

Preferred

clotrimazole (Lotrimin)

clotrimazole/betamethasone (Lotrisone)

econazole (Spectazole) ketoconazole (Nizoral) nystatin (Mycostatin)

nystatin/triamcinolone (Mycolog II)

Exelderm Naftin

Nizoral Shampoo

Oxistat

Requires Prior Authorization

Loprox

Loprox Shampoo

Mentax Penlac

Antivirals (Antivirals, General) Effective as of December 17, 2003

Preferred

acyclovir (Zovirax) amantadine (Symmetrel) rimantadine (Flumadine)

Cytovene Famvir Tamiflu Valcyte

Requires Prior Authorization

Relenza Valtrex

Cephalosporin and Related Agents (Cephalosporins, Second and Third Generation, Penicillins) Effective as of January 21, 2004

amoxicillin/clavulanate (Augmentin) cefaclor (Ceclor, CD)

Preferred

cefadroxil (Duricef) cefuroxime (Ceftin) cephalexin (Keflex) Augmentin ES-600, XR

Omnicef Spectracef

Requires Prior Authorization

Cedax Cefzil Lorabid Vantin

Fluoroquinolones (Quinolones) Effective as of December 17, 2003

<u>Preferred</u> <u>Requires Prior Authorization</u>

ofloxacin (Floxin) ciprofloxacin
Avelox, IV Floxin IV
Cipro, XR, IV Levaquin, IV
Maxaquin
Noroxin

Macrolides - Effective as of December 17, 2003

Preferred

erythromycin Biaxin, XL Dynabac Zithromax none

Tequin, IV

Requires Prior Authorization

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

CARDIOVASCULAR

Tarka

Aceon

Uniretic

Monopril, HCT

ACE Inhibitor/Calcium Channel Blocker Combination

Effective as of November 5, 2003

	<u>Preferred</u>	<u>Requires Prior Authorization</u>
Lexxel		none
Lotrel		

ACE Inhibitors (Hypotensives, ACE Inhibitors)

Effective as of December 3, 2003

<u>Preferred</u>	<u> </u>
captopril, HCTZ (Capoten,	Acc
Capozide)	Alta
enalapril, HCTZ (Vasotec,	Lot
Vaseretic)	Ma
lisinopril, HCTZ (Prinivil,	
Zestril,	
Prinzide, Zestoretic)	
moexipril (Univasc)	

Requires Prior Authorization

cupril, Accuretic tace tensin, HCT avik

Angiotensin Receptor Blockers (Hypotensives, Angiotensin Receptor Antagonist)

Effective as of November 19, 2003

Avapro, Avalide
Benicar, HCT
Cozaar, Hyzaar
Diovan, HCT
Micardis, HCT

Preferred

Requires Prior Authorization

Atacand, HCT Teveten, HCT

Beta Blockers (Alpha/Beta-Adrenergic Blocking Agents, **Beta-Adrenergic Blocking Agents)**

Effective as of November 5, 2003

<u>Preferred</u>		Requires Prior Authorization
acebutolol (Sectral) atenolol (Tenormin) betaxolol (Kerlone) bisoprolol (Zebeta) labetalol (Normodyne,	Cartrol Innopran XL Levatol	
L	1	

Calcium Channel Blocking Agents Effective as of December 3, 2003

Verelan) Dynacirc, CR Norvasc

Plendil Sular

<u>Preferred</u>	
diltiazem (Cardizem)	Cardene SF
diltiazem SR, ER (Cardizem SR,	Cardizem L
CD, Dilacor XR, Tiazac)	Covera-HS
nicardipine (Cardene)	Nimotop
nifedipine, SR (Adalat, CC,	Vascor
Procardia, XL)	Verelan PM
verapamil (Calan)	
verapamil ER, SR (Calan SR,	

R LA Requires Prior Authorization

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

Lipotropics, Other (Lipotropics, Bile Salt Sequestrants) Effective as of November 5, 2003

PreferredRequires Prior Authorizationcholestyramine (Questran, Light)
gemfibrozil (Lopid)
niacin (Niacor)Lofibra
WelcholAdvicor
Colestid
Niaspan
TricorZetia

Lipotropics, Statins (Lipotropics)

Effective as of December 3, 2003

<u>Preferred</u>	Requires Prior Authorization
lovastatin (Mevacor) Altocor Lescol, XL Lipitor Pravachol Zocor	Crestor Pravigard PAC

ENDOCRINE

Bone Resorption Suppression and Related Agents (Bone Resorption Inhibitors, Bone Formation Stim. Agents – Parathyroid Hormone)

Effective as of January 7, 2004

<u>Preferred</u>	Requires Prior Authorization
Actonel Fosamax	Didronel Evista
Miacalcin	Forteo

Estrogen Agents, Combination (Estrogenic Agents) Effective as of January 7, 2004

PreferredRequires Prior AuthorizationActivellaFemHRTCombipatchPrefestPremphasePrempro

Estrogen Agents, Oral and Transdermal (Estrogenic Agents) Effective as of January 7, 2004

<u>Preferred</u>	Requires Prior Authorization
estradiol (Estrace)	Cenestin
estradiol transdermal pato	ches Menest
(Estraderm)	
estropipate (Ogen, Ortho-	·Est)
Premarin	

Hypoglycemics, Insulin Effective as of January 21, 2004

<u>Preferred</u>	Requires Prior Authorization
Lantus	Humulin
Novolin	Humalog
Novolog	Humalog Mix
Novolog Mix	_

Hypoglycemics, TZDs (Hypoglycemics, Insulin-Response Enhancers)

Effective as of December 17, 2003

<u>Preferred</u>	Requires Prior Authorization
Avandia	Actos

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

GASTROINTESTINAL

Proton Pump Inhibitors (Gastric Acid Secretion Reducers)

Effective as of November 5, 2003

<u>Preferred</u> <u>Requires Prior Authorization</u>

Aciphex omeprazole
Prevacid Nexium
Prilosec

Protonix

RESPIRATORY

Inhaled Corticosteroids (Beta-Adrenergics and Glucocorticoids Combination, Glucocorticoids)

Effective as of November 5, 2003

<u>Preferred</u> <u>Requires Prior Authorization</u>

Advair Diskus Aerobid, Aerobid M

Aerobid, Aerobid M

Flovent, Rotadisk

Qvar

Pulmicort Respules (Ages 1-8)

Pulmicort Respules (Over Age 8, Under Age 1)

Pulmicort Turbuhaler

Leukotriene Receptor Antagonists

Effective as of November 5, 2003

<u>Preferred</u> <u>Requires Prior Authorization</u>

Singulair Accolate

Nasal Corticosteroids (Nasal Anti-Inflammatory Steroids)

Effective as of November 19, 2003

<u>Preferred</u> <u>Requires Prior Authorization</u>

flunisolide (Nasalide)

Flonase

Beconase AQ

Nasacort AQ

Nasonex Nasarel

Rhinocort Aqua

UROLOGIC

Benign Prostatic Hyperplasia (Alpha-Adrenergic Blocking Agents)

Effective as of November 5, 2003

Preferred Requires Prior Authorization in (Cardura) none

doxazosin (Cardura) terazosin (Hytrin)

Avodart Flomax Proscar

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

Instructions for the Pharmacist

When the pharmacist submits an on line-prescription for a non-preferred drug product whose class is on the preferred drug list, a message will appear "NON-PREF'D (PA req'd) MD call 1-800-932-3918." The pharmacist should:

- Refer to the PDL reference list
- Notify the customer that the drug prescribed is not a preferred drug
- Contact the prescriber explaining that the drug is a not a preferred drug
- Discuss the preferred drug options with the prescriber

If the prescriber agrees to switch to a preferred drug:

The pharmacist will:

For Original Prescriptions

- Draw a line through the original drug name, strength and directions
- Write the new drug name, strength, directions and number of refills
- Initial and note that the prescriber changed to a preferred drug

For Refills

- Pharmacist will note on the original prescription order that a switch has been made to a preferred drug and will create a new prescription number
- Pharmacist will not be required to obtain a new written prescription from the prescriber if a preferred drug is switched from the referenced original non-preferred prescription
- The prescription will be treated as a new prescription with the complement of refills as indicated by the prescriber

If the prescriber does not agree to switch to a preferred drug:

The pharmacist will explain to the prescriber that:

- He/she must contact the preauthorization center at First Health Services Corporation via telephone at 1-800-932-3918 or via facsimile at 1-800-932-3921
- The prescription cannot be filled until the preauthorization is completed

December 12, 2003

Note: For any multi-source product, the generic product(s) are usually preferred and branded innovator product(s) will be non-preferred.

After prior authorization has been obtained by the prescriber,

- The First Health Service Call Center will contact the pharmacy confirming pre-authorization
- The pharmacist can then complete the prescription, which was previously denied

When the prescriber cannot be contacted, the pharmacist is to call the preauthorization call center at 1-800-932-3918 to obtain approval for a 72-hour emergency supply of a non-preferred drug

- The pharmacist is to dispense the non-preferred drug
- Within the 72-hour window, the prescriber is to be contacted
- The pharmacist will receive a \$3.69 dispensing fee for the 72-hour supply and the recipient will not be charged a co-pay (e.g. \$0 co-pay)

When the prescriber is contacted after the 72-hour supply has been dispensed and the prescriber continues with the non-preferred drug:

- The prescriber is to be advised that he/she must obtain prior authorization before the remainder of the prescription can be dispensed
- After prior authorization has been established, the pharmacist can dispense the remainder of the prescription and receive an additional \$3.69 dispensing fee
- The appropriate co-pay will be charged to the recipient

When the prescriber is contacted after the 72-hour supply has been dispensed and the prescriber elects to switch to a preferred drug:

- Pharmacist completes the notation process previously described
- The pharmacist will receive a dispensing fee of \$4.69 and no-co-pay will be assessed to the recipient

When the pharmacist is having difficulty contacting the prescriber after the 72-hour supply has been dispensed, if necessary, a second 72-hour supply may be dispensed. However, the pharmacy <u>must</u> contact the Department for further instructions at 410-767-1455.